Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
X
Xayasak, Vanessa
Sarcoma Oncology Center
(
P 233
)
DNG64-CAR-V+ REGIMEN SHOWS CLINICAL BENEFIT IN PATIENTS WITH ADVANCED CCNG1 ONCOGENE EXPRESSING SARCOMAS (NCT04091295)
Vanessa Xayasak
Favorite
(
P 388
)
TRIAL IN PROGRESS: A PHASE 2 STUDY OF METRONOMIC TRABECTEDIN, GEMCITIBAINE, AND DACARBAZINE IN PREVIOUSLY TREATED ADVANCED SOFT TISSUE SARCOMA (NCT04535271)
Vanessa Xayasak
Favorite
(
P 396
)
EVALUATING THE SAFETY AND EFFICACY OF METRONOMIC GEMCITABINE, DOXORUBICIN, AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA: A PHASE 2 STUDY (NCT04535713)
Vanessa Xayasak
Favorite
Xhabija, Besa
University of Michigan
(
P 50
)
A NEW MURINE MODEL OF DEDIFFERENTIATED LIPOSARCOMA DEFINED BY HIGH PROLIFERATION AND METABOLIC ADAPTABILITY
Besa Xhabija
Favorite
Xiao, Guanghua
UT Southwestern Medical Center
(
P 168
)
LEVERAGING LARGE LANGUAGE MODELS FOR STRUCTURED INFORMATION EXTRACTION FROM EWING SARCOMA PATHOLOGY REPORTS
Guanghua Xiao
Favorite
Xia, Yanzhe
Sun Yat-sen University
(
P 193
)
CLINICAL ANALYSIS OF RIPRETINIB DOSE ESCALATION IN ADVANCED GISTS AFTER STANDARD DOSE PROGRESSION
Yanzhe Xia
Favorite
Xie, Chao
University of Florida
(
P 248
)
AN EX VIVO ASSAY TO PREDICT IMMUNOTHERAPY RESPONSE IN SARCOMA
Chao Xie
Favorite
Xie, Jinhan
Children's Cancer Institute
(
P 11
)
ESTABLISHMENT, CHARACTERIZATION AND RESEARCH APPLICATION OF EIGHT NOVEL PATIENT-DERIVED OSTEOSARCOMA CELL LINES
Jinhan Xie
Favorite
Xie, Lu
Musculoskeletal Tumor Centre, Peking University People's Hospital
(
P 75
)
CD248 AS A PROGNOSTIC MARKER IN OSTEOSARCOMA
Lu Xie
Favorite
Xu, Eric
Duke University Medical Center
(
P 58
)
PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
Eric Xu
Favorite
Xue, Wei
COG Data Center
(
P 250
)
OUTCOME OF INFANTS WITH RHABDOMYOSARCOMA: A REPORT FROM THE INTERNATIONAL SOFT TISSUE SARCOMA CONSORTIUM
Wei Xue
Favorite
Xu, Hairong
Department of Orthopaedic Oncology Surgery, Beijing Jishuitan Hospital, Peking University
(
P 361
)
PEXIDARTINIB FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMORS: CLINICAL EXPERIENCE FROM FIVE CHINESE PATIENTS
Hairong Xu
Favorite
(
P 407
)
PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Hairong Xu
Favorite
XU, Jie
Peking University People's Hospital
(
P 255
)
AN OPEN-LABEL, TWO-COHORT, PHASE 1A/B STUDY OF WEEKLY IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH VINCRISTINE AND TEMOZOLOMIDE (NALIRI-VT) IN PATIENTS WITH ADVANCED EWING SARCOMA
Jie XU
Favorite
Xu, Rui-Hua
Sun Yat-sen University Cancer Center
(
P 417
)
EFFICACY AND SAFETY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS
Rui-Hua Xu
Favorite
